Page last updated: 2024-08-17

tributyrin and Adenocarcinoma, Basal Cell

tributyrin has been researched along with Adenocarcinoma, Basal Cell in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Clarke, KO; Feinman, R; Harrison, LE1
Maurer, HR; Schröder, CP1

Other Studies

2 other study(ies) available for tributyrin and Adenocarcinoma, Basal Cell

ArticleYear
Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3.
    Cancer letters, 2001, Sep-28, Volume: 171, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Butyrates; Caspase 3; Caspases; CDC2-CDC28 Kinases; Cell Cycle Proteins; Colonic Neoplasms; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA-Binding Proteins; E2F Transcription Factors; E2F4 Transcription Factor; Enzyme Activation; G1 Phase; Neoplasm Proteins; Nuclear Proteins; Phenotype; Phenylbutyrates; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Transcription Factors; Triglycerides; Tumor Cells, Cultured

2001
Tributyrin-induced differentiation promotes apoptosis of LS 174T colon cancer cells in vitro.
    International journal of oncology, 2002, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Alkaline Phosphatase; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; Cell Differentiation; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Humans; Triglycerides; Tumor Cells, Cultured

2002